Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Lifecare ASA via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
Land | Norge |
---|---|
Lista | Oslo Bors |
Sektor | Hälsovård |
Industri | Medicinteknik |
2025-04-23 07:00:00
Bergen, Norway, 23 April 2025 - Lifecare ASA (LIFE), a medtech company developing next generation continuous glucose monitoring (CGM) solutions for diabetes management, today publishes an updated company presentation articulating the company’s long-term value creation opportunity.
The presentation is attached and available at: https://lifecare.no/investor/
Key highlights from the presentation:
Diabetes is a trillion-dollar global healthcare challenge
- CGMs the fastest growing diabetes tech segment, representing a USD 30 billion market opportunity
- Within CGMs, implantable solutions represent a USD 5 billion potential market
Strong value drivers in place 2025-2028
- Set to capitalize on “second mover” advantage, leveraging first mover regulatory approvals in the US
- Capital efficient path to commercialization with partner-led go-to-market strategy and minimal additional R&D
- Near-term value inflection points including veterinary market launch late 2025, CE mark in 2026, and European human market launch in 2027
Significant value creation potential
- Peak revenue potential of USD 1 billion + on realistic market assumptions
- Revenue sustainable at high levels long-term assuming conservative market share in a growing market
- EBITDA margin of 35%+